In an interview on CNBC’s Mad Money, Mick Farrell said ResMed only has about 15%-20% market penetration in the U.S. for sleep apnea products, so there is plenty of runway ahead.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RMD:
